publication venue for
- A simplified diagnosis algorithm for dysbetalipoproteinemia. 14:431-437. 2020
- Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia. 14:46-52. 2020
- A failure of standardization or a failure of the process of standardization. 12:1325-1326. 2018
- A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome. 12:506-510. 2018
- Polygenic Risk Score Predicts Cardiovascular Events in Familial Hypercholesterolemia. 11:787-788. 2017
- Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. 11:725-732.e5. 2017
- The 9p21.3 locus and cardiovascular risk in familial hypercholesterolemia. 11:406-412. 2017
- Familial partial lipodystrophy presenting as metabolic syndrome. 10:1488-1491. 2016
- Frameshift mutation in the APOA5 gene causing hypertriglyceridemia in a Pakistani family: Management and considerations for cardiovascular risk. 10:1272-1277. 2016
- Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. 9:741-750. 2015
- Successful reintroduction of statin therapy after statin-associated rhabdomyolysis. 9:594-596. 2015
- An assessment by the Statin Muscle Safety Task Force: 2014 update. 8:S58-S71. 2014
- Is the superiority of apoB over non–HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?. 7:626-631. 2013
- Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. 7:408-413. 2013
- Why is non−high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. 4:152-155. 2010
- When is equal not equal?. 4:83-88. 2010